Faculty Collaboration Database

Effect of methotrexate on relapse after bone-marrow transplantation for acute lymphoblastic leukaemia. International Bone Marrow Transplant Registry. Lancet 1989 Mar 11;1(8637):535-7

Date

03/11/1989

Pubmed ID

2564066

Scopus ID

2-s2.0-84921620400 (requires institutional sign-in at Scopus site)   24 Citations

Abstract

Data from 634 patients who received HLA-identical bone-marrow transplants for acute lymphoblastic leukaemia in first or second remission were analysed to examine the influence of mode of prophylaxis against graft versus host disease on rate of relapse of leukaemia. Methotrexate was associated with a significantly lower risk of leukaemia recurrence than were other methods of GVHD prophylaxis (relative risk 0.2, p less than 0.0003, for first-remission transplants; relative risk 0.3, p less than 0.0001, for second remission transplants). The decreased risk of relapse did not seem to be mediated via an impact on incidence or severity of graft versus host disease. A direct antileukaemia effect of methotrexate is the most likely mechanism.

Author

Mary M. Horowitz MD, MS Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Actuarial Analysis
Adolescent
Adult
Bone Marrow Transplantation
Child
Cyclosporins
Drug Evaluation
Graft vs Host Disease
Humans
Methotrexate
Multicenter Studies as Topic
Neoplasm Recurrence, Local
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Retrospective Studies